<div>
  <ul>
    <li>
      <p>
        Caris Life Sciences has teamed up with COTA Inc. to enhance its multi-modal data offerings to facilitate biopharmaceutical drug development and patient care.
      </p>
    </li>
    <li>
      <p>
        This collaboration will integrate Caris' diverse genomic, transcriptomic, proteomic, and imaging data and COTA's curated clinical data, generating a comprehensive, multi-modal data repository. It allows the creation of specific cohorts to examine resistance mechanisms, response determinants, and vital biomarkers to increase the success of clinical trials. The ultimate aim of this partnership is to boost research and AI strategies for creating novel cancer therapeutics. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/caris-life-sciences-and-cota-inc-announce-collaboration-to-expand-collective-multi-modal-data-offering-302130910.html">
      <b>Press release</b>
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

PROMINENT_CATEGORY

<div>
 <p>Caris Life Sciences is collaborating with COTA Inc. to improve its multi-modal data services for supporting biopharmaceutical drug development and patient care. The cooperation will merge Caris' vast genomic, transcriptomic, proteomic, and imaging data with COTA's refined clinical data, creating an all-encompassing, multi-modal data storehouse.</p>
 <p>This will allow the development of particular groups for studying resistance mechanisms, determining responses, and critical biomarkers to enhance clinical trial success rates. The primary goal of this alliance is to advance research and AI methodologies for developing new cancer drugs.</p>
</div>

Caris Life Sciences and COTA collaborate to enhance biopharmaceutical drug development and patient care

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
    <p>Caris Life Sciences and Merck KGaA have initiated a multi-year collaboration with the aim to create novel antibody-drug conjugates (ADC) for the treatment of cancer. In accordance with the partnership, Merck KGaA will provide Caris with an advance payment and funding for research. In addition, Caris will be eligible to receive milestone payments totalling up to USD 1.4 billion, based on the advancement of the project.</p>
    <p>The discovery division of Caris, Caris Discovery, utilizes the company's core molecular profiling operation to identify new druggable targets. This discovery process employs Caris' ADAPT Biotargeting platform and its dedicated research facility. Any new therapeutic targets discovered through this process are expected to be further developed by Merck KGaA.</p>
    <p>Merck KGaA will have global license rights to develop, manufacture, and distribute the ADC therapeutics produced as a result of this partnership.</p>
</div>

Caris Life Sciences and Merck KGaA partner to develop cancer-targeted first-in-class antibody drug conjugates

<div>
 <p>Caris Life Sciences and Merck KGaA have partnered for multiple years to discover and develop new antibody-drug conjugates (ADC) to treat cancer. In the agreement, Merck KGaA will make an upfront payment to Caris, provide research funding, and make additional milestone payments that could total up to USD 1.4 billion, depending upon the progress.</p>
 <p>Caris Discovery, the company's core molecular profiling business, will identify new, druggable targets using its ADAPT Biotargeting platform and research facility. These targets are expected to be developed further by Merck KGaA. The company will have global license rights to develop, manufacture, and market ADC therapeutics that result from this partnership.</p>
</div>

DISRUPTOR_PRESENT

<div><ul><li><p>Genetic testing company Caris Life Sciences has signed a multi-year deal with health tech company Pramana to digitalize about 1.5 million pathology slide specimens per annum for use with Caris' AI-developed software to support treatment decisions and clinical trial recruitment.</p></li><li><p>Massachusetts-based Pramana is expected to use its Spectral scanners and Intelligent Acquisition image recognition software to provide digital scans of pathology specimens in support of Caris' digital pathology business.</p></li><li><p>In addition, the two companies have created a new industry best benchmark for "no tissue left behind" for molecular pathology labs to ensure complete replication of the physical slide including tiny tissue fragments located in the farthest corners of a glass slide.</p></li></ul></div>

All Updates

Caris Life Sciences and COTA collaborate to enhance biopharmaceutical drug development and patient care

Caris Life Sciences and Merck KGaA partner to develop cancer-targeted first-in-class antibody drug conjugates

Caris Life Sciences and Merck KGaA partner to develop cancer-targeted first-in-class antibody drug conjugates

Caris Life Sciences partners with Pramana to digitalize pathology slide specimens

SWOG Cancer Research Network joins Caris Precision Oncology Alliance

Caris Life Sciences partners with ConcertAI to create clinico-genomic platform

Caris Life Sciences partners with Flare Therapeutics to advance Flare’s precision oncology pipeline

Caris Life Sciences partners with Incyte

Caris Life Sciences has secured USD 400 million in debt funding

Caris Life Sciences partner with Hummingbird Bioscience to advance anti-HER3 therapy

Precision Medicine

Caris Life Sciences and COTA collaborate to enhance biopharmaceutical drug development and patient care

Contact us